SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Brookline Capital Markets upped their Q3 2026 earnings estimates for SAB Biotherapeutics in a research report issued to clients and investors on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.24) per share for the quarter, up [...]